 The potential MTD (10 pts) for the combination of LPT with VNR given iv on a D1 & D8 q3w according to the initial dose escalation schedule is : LPT 1,000 mg/day continuous VNR 22.5 mg/m² D1 D8 An intermediate dose level LPT 1,250 mg/ VNR 22.5 mg/m² has been added, 6 patients are already enrolled and 3 more patients are planned  PK interaction (NS so far but strong tendency)
OBJECTIVES & ENDPOINTS

 Background
Lapatinib is effective in overexpressing HER2 LAMBC pts. Following anthracyclines, taxanes and capecitabine, VNR is an active agent in metastatic setting. Both drugs use the same main metabolic pathway : Cytochrome P450 3A4. We investigated the combination of LPT + VNR, seeking the recommended dose for further phase II studies, and looking for the PK interactions between the 2 drugs.
 Methods
Women with HER2+ LAMBC, in progression after ≤ 2 lines of trastuzumab-based treatment were treated with a 7 day (D-7 to D0) loading dose of LPT before starting VNR on a D1 and D8 q3w iv regimen. LPT was given po continuously. G-CSF as primary prophylaxis of febrile neutropenia (FN) was not permitted. Dose levels (DL) (LPT mg/ VNR mg/m²) ranged from 750/20 to 1250/30 with 3 patients per DL. PK samples were collected on 7 points on D1 of cycle 1 for LPT and VNR dosages. PK time points analysis was performed on plasma for LPT and whole blood for VNR. For both drugs the analytical method was Ultra Performance Liquid Chromatography (UPLC) coupled with tandem mass spectrometry (MS-MS) as detection. VNR PK parameters were estimated by nonlinear mixed effect modeling (NONMEM) and LPT PK parameters were estimated by non compartmental software (MicroPharm).
 Results
Seventeen pts and 68 PK time points were available for VNR analysis. VNR was ascribed to a tri-compartment model. When considering all VNR data together, VNR clearance (CL) was 37.8±16.7 L/h, while it showed a gradual decrease according to specifi c dose of LPT: 47.5±20.4 L/h for LPT 750 mg (3 patients) vs 35.6±4.3 L/h for pooled data for LPT 1000 and 1250 (14 patients). This trend was not signifi cant likely due to low number of patients treated at lower dose of LPT, while no signifi cant difference was observed between LPT 1000 and LPT 1250. The mean elimination half life time (t 1/2) of VNR was 0.12 h. Six patients and 42 PK time points were analyzed for LPT. LPT CL were respectively 83. 
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